Send mail to Author

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer (Article)

Please indicate your contact information and select, which author you want to contact.



 
__    __    _____   __    __   _    _    __   __     ___    
\ \\ / //  |  ___|| \ \\ / // | || | ||  \ \\/ //   / _ \\  
 \ \/ //   | ||__    \ \/ //  | || | ||   \   //   | / \ || 
  \  //    | ||__     \  //   | \\_/ ||   / . \\   | \_/ || 
   \//     |_____||    \//     \____//   /_//\_\\   \___//  
    `      `-----`      `       `---`    `-`  --`   `---`   
                                                            
 


Back to frontdoor view